- Abstract Number: 0016
Role of TP53 in Inflammatory Reprogramming of Rheumatoid Arthritis Synovial Fibroblasts
- Abstract Number: 2429
Romosozumab versus Denosumab in High-risk Patients Treated with Glucocorticoids: Interim 12-month Results from a Pilot Randomized Controlled Trial
- Abstract Number: 2088
Room for Racial and Ethnic Diversity in Adult Rheumatology Fellowship Pipeline
- Abstract Number: 0455
Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Inhibits Peripheral T Cell Proliferation and Cytokine Secretion and Reduces Circulating PD-1 High Expressing CD4 and CD8 T Cells: Results from a Phase 1 Healthy Volunteer Clinical Trial
- Abstract Number: 1484
Ruminococcus Implicated in the Clinical Development of Lupus Nephritis: A Systematic Review of the Literature
- Abstract Number: 0941
RUNX1 Expression and Binding Site Accessibility Is Associated with Increased Disease Severity in Systemic Sclerosis
- Abstract Number: 1759
Runx1 Is a Key Transcription Factor That Drives Synovial Fibroblast Pathogenicity in Rheumatoid Arthritis
- Abstract Number: 1892
Sacroiliac Bone Marrow Oedema on Postpartum MRI Does Not Result in Significant SpA-like Structural Lesions: Results of a 5-year Follow-up Study
- Abstract Number: 0246
Safety & Efficacy of SEL-212 in Patients with Gout Refractory to Conventional Treatment: Primary Outcomes from Two Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Studies
- Abstract Number: 1796
Safety & ImmUnogenicity of COVID-19 VaCcines in SystEmic immunE Mediated Inflammatory Diseases (SUCCEED)
- Abstract Number: 2147
Safety and Effectiveness in Cycling Between Non-Selective and Selective JAKi in a Multi-Center Registry of Rheumatoid Arthritis in the Middle East
- Abstract Number: 0686
Safety and Efficacy of Avacopan in Patients 65 Years and Older with ANCA-Associated Vasculitis
- Abstract Number: 0268
Safety and Efficacy of CT-guided Percutaneous Infra-Renal Periaortic Biopsies in Suspected Retroperitoneal Fibrosis
- Abstract Number: 2162
Safety and Efficacy of Filgotinib: An Update from the DARWIN 3 Phase 2 Long-term Extension with a Maximum of 8.2 Years of Exposure
- Abstract Number: 2490
Safety and Efficacy of Mycophenolate Mofetil in New-onset Systemic Lupus Erythematosus with High Titer of Anti-dsDNA Antibody and Without Major Organ Involvement: A Multicenter Randomized Controlled Trial
- « Previous Page
- 1
- …
- 136
- 137
- 138
- 139
- 140
- …
- 177
- Next Page »